

YANG Zhenjun (Ph.D.)

Academic qualifications:

- 1982-1987: B. Sci. Beijing Medical College, Beijing, China
1995-1998: Ph.D. Beijing Medical College, Beijing, China

Previous academic positions held:

- 1987-1995: Assistant Professor, Department of Pharmacy, Beijing Medical College, China
1998-2000: Associate Professor, Department of Pharmacy, Beijing Medical College, China

Present academic position:

- 2002-now: Professor, Department of Pharmacy, Beijing Medical College, China

Previous relevant research work:

Modified antisense oligonucleotides and siRNA drugs; New techniques based on aptamers for disease detection.

Publication records:

Section A-Five most representative publications in the recent five years (* Corresponding Author)

1. J Sun, C Qiu, YP Diao, W Wei, HW Jin, Y Zheng, JC Wang*, LH Zhang, **ZJ Yang***, Delivery pathway regulation of 3',3'-bis-peptide-siRNA conjugate by nano-carrier architecture engineering, *Molecular Therapy-Nucleic Acids*, 2018, 10, 75-90. SCI IF 6.392
2. KF Li, JL Deng, HW Jin, XM Fan, LY Li, Y Zhao, Z Guan*, Y Wu, LH Zhang, **ZJ Yang***, Chemical modification improves stability and targeting capability of DNA aptamer targeted Tenascin-C, *Org. Biomol. Chem.*, 2017, 15, 1174-1182. SCI IF 3.562.
3. XT Yang, YJ Zhu, C Wang, Z Guan, LH Zhang, **ZJ Yang***, Alkylation of phosphorothioated thrombin binding aptamer improves the selectivity of inhibiting tumor cell proliferation upon anticoagulation, *Biochim. Biophys. Acta-General Subjects(BBA Gen)*, 2017, 1861, 1864-1869. SCI IF 5.083(4.805)
4. Y. Ma, S. Liu, Y.S. Wang, Y.H. Zhao, Y. Huang, L.J. Zhong, L.H. Zhang, **Z.J. Yang***. D-Isonucleosides incorporation at terminal and in the middle of siRNA duplexes exhibiting high gene silencing efficacy and nuclease resistance. *Org. Biomol. Chem.*, 2017, 15, 5161–5170. SCI IF 3.562.
5. XM Fan, LD Sun, KF Li, XT Yang, BB Cai, YF Zhang, YJ Zhu, Y Ma, Z Guan, Y Wu, LH Zhang, **ZJ Yang***, Bioactivity of D-L-isonucleoside- and 2'-deoxyinosine-incorporated aptamer AS1411s and their regulation on DNA replication and miRNA expression, *Mol. Ther.-Nucleic Acids*, 2017, 9, 218- 229. SCI IF 6.392.

Section B - Five representative publications beyond the recent five-year period with the latest publication entered first

6. XY Song, XX Wang, Y Ma, ZC Liang, **ZJ Yang**, HQ Cao, Site-specific modification using

- the 2'-methoxyethyl group improves the specificity and activity of siRNAs, *Mol. Ther.-Nucleic Acids*, 2017, 9(11), 242-250. SCI IF 6.392.
7. Z.X. Zhou, S. Liu, Y.F. Zhang, X.T. Yang, Y. Ma, Z. Guan, Y. Wu*, L.H. Zhang, Z.J. Yang*. Reductive liposome encapsulation of cRGD-siRNA conjugates for enhanced targeting to cancer cells, *Inter. J. Nanomed.*, 2017, 12, 7255-7272. SCI IF 5.008
 8. XF Ma, J Sun, YF Wu, Y Zheng, MZ Yu, C Qiu, XW Pei, L Wei, YJ Niu, WH Pang, ZJ Yang*, JC Wang*, Q Zhang, Mechanistic study of the roles of disulfide-bridge in H-shape gemini-like cationic lipid based siRNA delivery, *J. Control. Release*, 2016, 235, 99-111. SCI IF 8.407
 9. XM Fan, LD Sun, Y Wu, LH Zhang, ZJ Yang*, Bioactivity of 2'-deoxyinosine incorporated-aptamer AS1411, *Sci. Rep.*, 2016, 6, 25799. DOI:10.1038/srep25799. SCI IF 5.578
 10. XM Fan, YF Zhang, HY He, XJ Liu, Y Ma, J Sun, Y Huang, XF Wang, Y Wu*, LH Zhang, ZJ Yang*, Biological properties of 3',3"-bis-peptide-siRNA conjugate in vitro and in vivo, *Bioconjugate Chem.*, 2016, 27, 1131-1142. SCI IF 4.862.

Award:

Funded Projects

2017ZX09303013 (NFSC)	Research on innovative varieties of nucleic acid drugs (2017.1.1-2020.12, ¥7530,000)
21778006 (NFSC)	Delivery system based on nucleoside base liposomes (2018.1-2021.12, ¥780,000)